{"id":"W2920183853","doi":"10.1007/s40264-018-00783-1","title":"Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis","year":2019,"lang":"en","type":"review","venue":"Drug Safety","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Victoria Hospital; Western University; University of Calgary; Robarts Clinical Trials","funders":"","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Natalizumab; Adverse effect; Internal medicine; Maintenance therapy; Inflammatory bowel disease; Infliximab; Crohn's disease; Placebo; Gastroenterology; Immunology; Disease; Pathology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000222184,0.0003119807,0.0007534029,0.00005657247,0.00004025673,0.0000106517,0.0002048825,0.0001285373,0.00001701447],"category_scores_gemma":[0.00002733115,0.0002093915,0.0003676517,0.00006701266,0.0001157329,0.000003047132,0.00005761228,0.00008620192,0.000002051656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008735894,"about_ca_system_score_gemma":0.0005309257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004560276,"about_ca_topic_score_gemma":0.0001522629,"domain_scores_codex":[0.9983034,0.0004548776,0.0005304753,0.0003703063,0.0001615475,0.0001793874],"domain_scores_gemma":[0.9987133,0.00007907522,0.0004069527,0.0006537653,0.00006750915,0.00007936663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001204253,0.001177187,0.00337879,0.01653174,0.001043558,0.0002597304,0.0008476432,0.00007958848,0.000002946954,0.002031081,0.0002224555,0.973221],"study_design_scores_gemma":[0.001398635,0.0002120317,0.390014,0.001602893,0.001455425,0.000004929585,0.0001215789,0.00002375284,0.000006933425,0.00005897194,0.6047292,0.0003716286],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02856198,0.9651335,0.000009350993,0.00001442277,0.00009394225,0.002045414,0.003277504,0.000003072576,0.0008608256],"genre_scores_gemma":[0.01495924,0.9837621,0.00004605562,0.00001346846,0.00007445376,0.0001747154,0.0007548457,0.00002703172,0.0001881101],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9728494,"threshold_uncertainty_score":0.8538738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01567007994426291,"score_gpt":0.3114790885300934,"score_spread":0.2958090085858305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}